US pharmaceutical and biotechnology company Moderna Inc (NASDAQ:MRNA) has said that deliveries of its COVID-19 vaccine are on track to meet the number of doses previously communicated to governments, Reuters news agency reported on Wednesday.
According to an email sent to Reuters from the company: "Moderna is committed to meeting all quarterly contractual delivery agreements with the European Commission and individual Member States."
Based in Cambridge, Massachusetts, Moderna focuses on drug discovery, drug development and vaccine technologies based on messenger RNA (mRNA).
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine